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Abstract
Background and aims
Hepatic macrophages (Kupffer cells) are involved in the immunopathology of alcoholic liver
disease (ALD). The mannose receptor (MR, CD206), expressed primarily by macrophages,
mediates endocytosis, antigen presentation and T-cell activation. A soluble form, sMR, has
recently been identified in humans.
We aimed to study plasma sMR levels and its correlation with disease severity and sur-
vival in ALD patients.
Methods
We included 50 patients with alcoholic hepatitis (AH), 68 alcoholic cirrhosis (AC) patients
(Child-Pugh A (23), B (24), C (21)), and 21 healthy controls (HC). Liver status was described
by the Glasgow Alcoholic Hepatitis Score (GAHS), Child-Pugh (CP) and MELD-scores, and
in AC patients the hepatic venous pressure gradient (HVPG) was measured by liver vein
catheterisation. We used Kaplan-Meier statistics for short-term survival (84-days) in AH
patients and long-term (4 years) in AC patients. We measured plasma sMR by ELISA.
Results
Median sMR concentrations were significantly elevated in AH 1.32(IQR:0.69) and AC 0.46
(0.5) compared to HC 0.2(0.06) mg/L; p<0.001 and increased in a stepwise manner with the
CP-score (p<0.001). In AC sMR predicted portal hypertension (HVPG10 mmHg) with an
area under the Receiver Operator Characteristics curve of 0.86 and a high sMR cut-off
(>0.43 mg/l) was associated with increased mortality (p = 0.005).
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Conclusion
The soluble mannose receptor is elevated in alcoholic liver disease, especially in patients
with AH. Its blood level predicts portal hypertension and long-term mortality in AC patients.
Introduction
The immunopathology of alcoholic liver disease (ALD) is incompletely understood and treat-
ment options are limited. Therefore, identification of key pathophysiological components and
possible targets for intervention is a priority in ALD.
Resident hepatic macrophages (Kupffer cells) are central in the current immunopathologi-
cal understanding of ALD and we have previously shown that soluble CD163, the hemoglo-
bin-haptoglobin scavenger receptor and a specific marker of macrophage activation, is highly
elevated in ALD and originates from Kupffer cells[1–3]. This study focuses on the functionally
different macrophage receptor, the mannose receptor (MR, CD206, MRC1) and its relation to
clinical endpoints in ALD. The MR is expressed primarily by subsets of macrophages and by
the comparatively scarcer dendritic cells, a soluble form (sMR) has recently been identified in
humans [4]. MR is a pattern recognition receptor with a broad range of ligands including
mannose, sulphated carbohydrates and collagen. The functions of the mannose receptor
include endocytosis of microorganisms as well as facilitation of antigen presentation and sub-
sequent induction of the associated immune responses[5, 6]. Furthermore, sMR has a meta-
bolic role in the clearance of glycoproteins with degradation of endogenous glycoproteins such
as β-glucuronidase and procollagen, which are up-regulated during inflammation[7]. In mice
macrophages increase expression of the MR and its soluble form upon stimulation with IL-4
and IL-10, but the exact mechanism of sMR release in humans is unknown[8, 9]. sMR levels
are elevated in critically ill patients receiving intensive care and predict survival in patients
with pneumococcal bacteraemia and patients with acute on chronic liver failure[10–12].
In ALD, Kupffer cell activation likely occurs as a consequence of bacterial translocation
from the gut to the liver. Early animal studies have shown that ethanol-mediated leakage of gut
endotoxins to the liver leads to activation of Kupffer cells and initiation of hepatic inflamma-
tion [13–15]. This mechanism seems to be important in humans as well, and both increased
gut permeability as well as increased serum levels of bacteria and bacterial products have been
demonstrated in human ALD [1, 16–20]. The exact role of Kupffer cells remains controversial
with different studies showing booth beneficial and deleterious effects of the cells. [21, 22]
This study was conducted to pursue our previous findings of Kupffer cell activation in
ALD, and to obtain corroborative and functionally independent confirmation of it´s role. We
hypothesize that plasma concentrations of sMR are higher in ALD patients compared with
healthy controls, that sMR is associated with ALD disease severity and portal hypertension,
and that it can predict clinical endpoints. For this purpose we investigated plasma levels of
sMR in ALD patients with alcoholic hepatitis, alcoholic cirrhosis, and healthy controls and
measured the hepatic venous pressure gradient (HVPG) by liver vein catheterization, and
investigated the association with short- and long-term survival in AH and AC patients,
Methods
Patients
We conducted a cohort study on three groups: 1) 50 patients admitted with acute AH; 2) 68
patients with alcoholic cirrhosis (AC) with different CP-score; and 3) 21 healthy persons with
no history of liver or other diseases.
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The AH patients were consecutively included using the following inclusion criteria: A first
time diagnosis of AH by a combination of physical and laboratory criteria: A history of exces-
sive alcohol ingestion (10 units or more per day) until at least three weeks before admission;
acute jaundice (developed over at most 2 weeks, serum bilirubin > 80 μmol/L). The diagnosis
was verified by liver biopsy in 10 patients. Exclusion criteria were: viral hepatitis, autoimmune
liver disease, bile duct obstruction, liver tumors or any other cancer, presence of an infectious
focus (either clinically assessed or based on chest x-ray, urine samples or ascites puncture), age
below 18 or above 75 years, ongoing gastrointestinal bleeding or bleeding within the previous
three months, or any prior immune-modulating therapy. Patients were recruited from four
hospitals in the Aarhus region in Denmark. The patients were stratified according to the Glas-
gow Alcoholic Hepatitis Score (GAHS) [23]. Those with a GAHS < 9 were given moderate
hyper-alimentation (a daily energy consumption of 35–49 Kcal/kg body weight and a daily
protein intake of 1.2–1.5 g/kg) and standard supportive medical care, and those with a GAHS
9 were treated orally with pentoxifylline 400 mg TID (Trental1, Sanofi Paris, France) accord-
ing to the national guidelines at the time of the study. Clinical status was also assessed according
to the Model for End-stage Liver Disease (MELD) and the Child-Pugh score[24–26]. The infec-
tious status at baseline was recorded. The patients were followed-up for 30 days and blood sam-
ples were collected at study entry and at day 7, 14, 21, & 30. Entry blood samples were secured
before initiation of treatment. The mortality by day 84 (12-weeks) was recorded in the AH
patients. Baseline data and baseline sMR levels from this cohort have previously been reported
[1, 4]. No patients received blood transfusions during the study period.
The AC patients (n = 68 Child-Pugh A: n = 23, B: n = 24, C: n = 21) were all set up for clini-
cal routine liver vein catheterization. The HVPG was determined using Swan-Ganz balloon
catheters as previously described [27]. Blood was collected during catheterisation. Baseline
data has partly been reported previously [2]. None of the patients had signs of alcoholic hepati-
tis, infection or had fever at examination and none of the patients were treated with antibiotics.
The diagnosis of cirrhosis was based on a combination of clinical and biochemical parameters
as well as ultrasound or CT-scan. The patients underwent routine clinical assessment of the
severity of liver disease by CP-class and MELD score. The galactose elimination capacity
(GEC) as a measure of metabolic liver function was determined as previously described [28].
Clinically significant portal hypertension (CSPH) was defined by a HVPG10 mmHg mea-
sured during hepatic vein catheterization.
Survival data was collected after four years.
The 21 control persons were referred for hemodynamic investigation to exclude splanchnic
perfusion disorders, for which no evidence was found. The HVPG was determined by the
same procedure as in the AC patients.
All participants gave informed consent in accordance with the Helsinki Declaration, and
the study was approved by the National Committee on Health Research Ethics and the Danish
Data Protection Agency (J-No. 2008-41-2020) & (J.nr. 2008-41-2836).
Biochemical analysis of sMR
The plasma concentration of sMR was determined by ELISA as previously described.[4]
The maximum inter-assay coefficient of variation was 15%, and the intra-assay coefficient
of variation was below 10%.
Biochemical analysis of soluble cytokines interleukin 17a (IL-17a) & interleukin 22 (IL-22)
IL-22 has a protective role in AH, and to investigate the relationship between sMR and
other parts of the immune system we measured IL-22 and the related pro-inflammatory cyto-
kine IL-17a in 20 randomly selected AH patients.
Soluble mannose receptor as biomarker in alcoholic liver disease
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The plasma concentrations of IL-17A, IL-22 were measured with ELISA kits (eBioscience)
as previously described[29]. The samples and standards were analysed in duplicate, and the
average optical density, minus the average value of the blanks, was used to calculate the con-
centration of a given sample based on the standard curve. The lower detection limit was deter-
mined as the value of the average of the blanks plus 2 standard deviations, which resulted in
cut-off values of 2.72 pg/ml (IL-17A), 9.04 pg/ml (IL-22). The values below the detection limit
were assigned the cut-off value.
Flow cytometry
To investigate whether peripheral monocytes express MR and therefore could be a source of
sMR, we studied the MR expression using flow cytometry. 20 patients with AH, 10 patients
with AC, and 10 HCs was studied. Peripheral blood mononuclear cells were isolated by Ficoll-
Hypaque (GE Healthcare Bio-sciences, Uppsala, Sweden) from EDTA whole blood samples.
Samples were stored at -140˚C until en bloc analyses. Cells were thawed in PBS containing
20% heat-inactivated pooled human AB-serum and blocked with 10 μl heat-inactivated mouse
serum (Invitrogen, Carlsbad, California, USA) before staining with optimized amounts of fluo-
rescent-conjugated antibodies; CD14-APC (clone MFP9; BD Bioscience, San Diego, CA),
CD206-FITC (clone 19.2; BD Bioscience, San Diego, CA). Relevant isotype controls were
included. The samples were analysed within 24 hours of preparation using a FACSCanto
instrument (BD Bioscience). Data analyses were carried out using FlowJo v10.1 (Tree Star Inc.,
Ashland, OR). We report the relative fluorescent intensity (MFI) of sMR on the CD14+
monocytes.
Statistical analyses
We used the Kruskal-Wallis test followed by Mann-Whitney test to study differences between
groups. The relationships between sMR and clinical and biochemical variables were analysed
by Spearman’s rank correlation. We examined if sMR was independently associated with
CSPH by multiple logistic regression analyses, including the MELD-score, GEC and C-reactive
protein (CRP) in the model.
We used Receiver Operator Characteristics (ROC) analyses to evaluate the overall capability
of the sMR to predict clinically significant portal hypertension (CSPH) defined as a HVPG
10 mmHg. Using the ROC curve, a cut-off point was selected for predicting CSPH. The diag-
nostic accuracy of the cut-off was determined by calculating sensitivity, specificity, positive
predictive value (PPV) and negative predictive value (NPV). Healthy persons were excluded
for ROC-analysis. In the AH patients, an analysis of variance for repeated measurements with
Greenhouse–Geisser correction for sphericity was performed for a comparison of protein lev-
els over time. To ensure normally distributed variables, logarithmic transformation was used
where appropriate. Histograms and Q–Q plots were used to check normality.
All data are expressed as median with inter-quartile range, and P-values0.05 were consid-
ered statistically significant. STATA version 11.2 1StataCorp LP was used for the data
analyses.
Results
Patients
Age and gender distributions were similar in the three study groups (Table 1). As expected, the
patients with AH displayed a more severe liver dysfunction than the AC patients. No patient
Soluble mannose receptor as biomarker in alcoholic liver disease
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displayed signs of infection at study entry; however, eight AH patients (16%) developed blood
culture positive infection during the 30-day follow up.
sMR was elevated in alcoholic liver disease
At baseline, the plasma sMR concentration in the AH patients was approximately 3-fold higher
than in the cirrhosis patients and nearly 7-fold higher than in the healthy persons (AH 1.32
(0.69), AC 0.46(0.5), HC 0.2(0.06) mg/L; p< 0.001, Fig 1). In AC patients, the sMR concentra-
tions increased in a stepwise manner according to the Child-Pugh score. (Fig 2, p<0.05) sMR
levels were higher in patients with ascites compared to patients without ascites, and this was
the case for both AH patients (1.5 vs 1.1 mg/L; p = 0.003) and AC patients (0.7 vs 0.3 mg/L;
p<0.001).
In the AH patients, the sMR concentrations was unchanged during the 30-days follow-up
period (p = 0.07; Fig 3). There was no difference at baseline in sMR levels between patients
who later developed infection (and subsequently received antibiotic treatment) and those who
did not (1.35 vs 1.30 mg/l; p = 0.99). However, sMR levels rose in patients who developed
infection, but this rise in sMR level did not reach statistical significance (p = 0.33 repeated
measures ANOVA, Fig 4). We observed no differences in sMR levels whether the patients
were treated with Pentoxifylline or not (p = 0.9).
Internal correlations
In AH patients, baseline analysis showed statistically significant correlations between sMR and
Child-Pugh score (r = 0.41; p = 0.003), and albumin (r = 0.37; p = 0.009), but sMR did not
Table 1. Study entry characteristics of patients with alcoholic hepatitis and patients with stable alcoholic liver cirrhosis and healthy persons
(Data are median (interquartile range)).
Alcoholic Hepatitis Alcoholic cirrhosis Healthy Controls
Gender: F/M 16 / 34 16 / 52 7 / 13
Age (years) 53 (11) ++ 58 (12) * 51 (8)
Weight (kg) 75.9 (25) 75 (25) 58 (25)
Height (cm) 174 (11) * 173 (12) 166 (16)
BMI 24 (6) 25 (5) 25 (8)
ALT (U/l) 47 (39) 39 (27) 30 (10)
Sodium (mmol/l) 132 (7) * ++ 139 (6) * 143 (3)
Bilirubin (μmol/l) 283 (255) * ++ 18 (14) * 7 (12)
Alkaline phosphatase (U/l) 203 (149) * ++ 169 (127) 124 (116)
Hemoglobin (mmol/l) 6.7 (1) 7.4 (2) NA
Creatinine (μmol/l) 64 (38) ++ 78 (33) 72 (14)
INR 1.9 (0.7) * ++ 1.3 (0.3) * 1.05 (0.1)
Albumin (g/l) 27 (8) * ++ 34 (10) * 41 (7.7)
MELD 21 (11) 9 (6)
GAHS 9 (2)
Child Pugh Score 11 (2) 7 (4)
Ascites (yes/no) (31/19) (37/31) NO
ALT = Alanine aminotransferase, MELD = Model for End-stage Liver Disease, GAHS = Glasgow Alcoholic Hepatitis Score
INR = International Normalised Ratio.
*p<0.05 pt. vs controls
++p<0.05 AH. vs AC
https://doi.org/10.1371/journal.pone.0189345.t001
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correlate to any other clinical or biochemical measures including the GAHS score and cyto-
kines IL-17a (mean 4.0 pg/ml (IQR 2.5) rho -0.2 p = 0.4) and IL-22 (mean 50 pg/ml (IQR 45)
rho -0.13 p = 0.58)
At variance, in the AC patients we observed significant correlations between sMR and both
clinical and biochemical parameters: The Child-Pugh score (r = 0.71; p< 0.001), the MELD
score (r = 0.45; p = 0.002), albumin (r = 0.72; p< 0.001), INR (r = 0.46; p< 0.001), CRP
(r = 0.52; p< 0.001), and bilirubin (r = 0.36; p = 0.003).
Relationship between sMR and HVPG (alcoholic cirrhosis patients only)
sMR correlated positively with HVPG (r = 0.52, P<0.001) and sMR was independently associ-
ated with CSPH after adjustment for CRP, MELD-score and GEC, (p = 0.03) in multiple logis-
tic regression analysis, Table 2.
The ROC analysis showed sMR to be a strong predictor of portal hypertension (AUC
ROC = 0.86) (Fig 5). For further analysis we chose a cut-off for sMR at 0.43 mg/L equal to the
upper normal level. At this cut-off sMR had a sensitivity of 70% and a specificity of 100% for
the prediction of CSPH, corresponding to a positive predictive value of 100% and a negative
predicted value of 46%.
Mortality
The AH patients were followed up for 84-day mortality and within that period 11 of the 50
(22%) patients died. All but one of the diseased had a GAHS 9 on admission. We divided
the patients into two groups using the median level of sMR (1.3 mg/L) and this analysis
0
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Fig 1. sMR levels in Alcoholic hepatitis, Cirrhosis & healthy control subjects.
https://doi.org/10.1371/journal.pone.0189345.g001
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showed no difference in mortality between the groups (p = 0.46, log-rank test; data not
shown).
The alcoholic cirrhosis patients were followed up after four years and 41% (28/68) of the
patients died. We divided the patients into two groups using the same sMR cut-off of 0.43 mg/
Land the AC patients with a sMR above the cut-off had the higher mortality, 53% vs. 27%
(p = 0.03, Fig 6).
Blood monocyte MR & CD14 expression
There was an increase in the numbers of peripheral monocytes in patients with AH compared
to both the healthy controls and the AC patients (p = 0.006, data not shown), but we detected
no expression of membrane bound MR on CD14+ monocytes in neither patients or controls
by flow cytometry.
Discussion
The central finding of our study was the elevated plasma sMR in patients with alcoholic liver
disease, most markedly in the patients with alcoholic hepatitis. In the cirrhosis patients, sMR
rose with higher Child-Pugh score and with increasing portal pressure. Thus, the levels of sMR
accurately predicted if they had clinically significant portal hypertension and their long-term
mortality. These findings confirm and support our earlier reports based on sCD163 on the
role of the macrophages in ALD, using a new and functionally alternative immune-pathologi-
cal approach[30] [31].
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Fig 2. sMR in cirrhosis. sMR (mg/L) levels in healthy control subjects and patients with different degrees of liver
cirrhosis. P < 0.05 controls compared to patients with liver cirrhosis. P < 0.05 CP-C compared to CP-A and CP-B.
https://doi.org/10.1371/journal.pone.0189345.g002
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The major strength of our study is the relevant number of well-characterized patients with
ALD. We established the diagnosis of AH in our patients by using a combination of standard
clinical and biochemical criteria in accordance with several clinical trials [23, 32]; and the diag-
nosis was confirmed by liver biopsy in a subset of patients. Likewise, the diagnosis of cirrhosis
was made clinically by a combination of clinical, biochemical parameters as well as ultrasound
or CT-scan. Interestingly, we could not detect and impact of pentoxifyllin treatment on sMR
levels in the AH patients, and this possibly corresponds to the limited clinical impact of pen-
toxifyllin. It would be interesting to investigate the impact of steroid treatment on sMR levels
in AH patients.
A soluble form of the human MR was demonstrated in in vitro experiments in 1999, but it
was not till recently that sMR was detected in human blood samples [4, 33]. As a consequence,
few studies have investigated sMR in human disease. These studies demonstrated elevated
sMR in both critically ill sepsis patients and hepatitis C cirrhosis patients with levels in hepati-
tis C cirrhosis patients comparable to our AC patients [12, 34]). Of interest, patients with sepsis
and liver disease had the highest sMR levels. Recently it was demonstrated that sMR is elevated
in patients with acute-on-chronic liver disease (ACLF), and in relation to disease severity; and
further, that high sMR levels was an independent predictor for long-term survival in cirrhosis
patients without ACLF. Indeed, the addition of sMR to the CLIF-C Acute Decompensation
score significantly improved the prognostic performance of the original score[10, 35].
Recent alcohol intake may moderately increase sMR, and it is a limitation that we do not
have such information prior to study entry. However, if alcohol should be important we would
expect a rapid decline in sMR during the 30-day follow-up of the AH patients. More likely, the
0
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Fig 3. sMR in AH patients over time. sMR levels in Alcoholic hepatitis patients during the 30-day follow-up.
(p = 0.07, repeated measures ANOVA).
https://doi.org/10.1371/journal.pone.0189345.g003
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florid hepatic inflammation in AH has passed a threshold where alcohol cessation alone will
not be enough to dampen inflammation. It is also a limitation that we do not know to which
extent the dendritic cells contribute to the generation of sMR, and what pathophysiological
implications this might have. However, in comparison to Kupffer cells, dendritic cells are
sparse in the liver, and primarily located to the portal regions [36]. Very little is known about
clearance of sMR but renal excretion is unlikely owing to the molecular size of the protein
(approximately 170 KD). Decreased hepatic metabolism because of shunting might contribute
to the elevated levels seen in this study, but we don’t have any specific data to support this. We
believe that the origin of the high levels of sMR measured in our study is the liver and
Develop infection
No infection
0
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3
sM
R
 M
g/L
0 10 20 30
Days
Fig 4. sMR in AH patients by infection. sMR levels in Alcoholic hepatitis patients during the 30-day follow-up
allocated by patients who later developed infection n = 8 and patients who did not n = 42. (p = 0.07, repeated
measures ANOVA).
https://doi.org/10.1371/journal.pone.0189345.g004
Table 2. Multiple logistic regression analyses of the relationships between Clinically significant portal hypertension & sMR, CRP, GEC, and
MELD-score.
N = 60
Dependent Variable = CSPH Chi square = 0.0001
Predictor variables OR Std. Error p-Value Coeficients
sMR 7379.9 29678.0 0.027 8.90
CRP 0.9 0.1 0.286 -0.06
MELD-score 1.3 0.2 0.076 0.23
GEC 0.5 0.4 0.413 -0.78
CSPH = Clinically significant portal hypertension; GEC = Galactose elimination capacity; CRP = C-Reactive Protein.
https://doi.org/10.1371/journal.pone.0189345.t002
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predominantly the Kupffer cells. In line with a previous study we found that blood monocytes
did not express MR and are an unlikely source of sMR [12].
The functions of sMR are not completely understood, but the soluble part of the receptor
retains its binding capacity and thus may serve as a shuttle targeting circulating antigens to the
lymphoid organs [37, 38]. There seems to be a slight constitutive shedding of the MR and cer-
tain inflammatory mediators elicit extensive shedding. However, LPS is not among these
mediators and conversely appears to decrease the expression and shedding of the MR[33].
This is noteworthy because translocated bacteria and LPS presented to the liver is believed to
play a key role in the pathogenesis of ALD. Our results with an increased sMR thus cast doubts
on the importance of this mechanism. On the other hand sCD163, another marker of macro-
phage activation, increases its expression and shedding by LPS stimulation and is markedly
increased in ALD[1, 39]. These seemingly contradictory results may be reconciled by the
assumption that hepatic macrophage activation is effectuated by a variety of stimuli among
which LPS is an identified part.
The diversity of the stimulatory pathways notwithstanding, our study supports the occur-
rence of Kupffer cell activation in ALD and confirm that this may play a role in the immuno-
pathology which may also be corroborated by the repeatedly demonstrated associations of
macrophage activation markers, in this case sMR, with clinically important endpoints. Thus,
in the AC patients, the ROC-analysis showed a very high positive predictive value of an
increased sMR for clinically significant portal hypertension (>10 mmHg). It is well known
that hepatic inflammation leads to portal hypertension and we believe the sMR correlation
with CSPH mirrors this. Several non-invasive methods for identifying CSPH are under
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Fig 5. sMR as a predictor of portal hypertension. Receiver operating characteristic (ROC) analysis of sMR as a
predictor for CSPH in patients with alcoholic cirrhosis.
https://doi.org/10.1371/journal.pone.0189345.g005
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investigation and sMR measurements may contribute to this field alone or in combinations
[30]. Given its properties as an endocytic receptor, MR might also be a potential target for
intervention with antibody bound compounds. Such proof of concept already exists for the
endocytic macrophage receptor CD163. [40, 41]
In conclusion, the blood concentration of the soluble mannose receptor sMR is elevated in
ALD, especially in patients with AH. Its level is independently associated with severe portal
hypertension and long-term mortality in cirrhosis. Our study confirms and expands our previ-
ous findings of macrophage activation in ALD by a different biological approach and possibly
motivates intervention studies.
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of sMR. The cut-off used was 0.43 (mg/L) (P = 0.03, Log-rank).
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